Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Gubra ASHAM:PI3 -1.34%53 Debt-to-Equity is 0.09 as of Dec. 2025, which is 74% below its 10-year median of 0.35. GuruFocus rates HAM:PI3 with a GF Score™ of 53/100 and a GF Value™ of €388.86 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 966 Biotechnology companies, Gubra AS ranks better than 62.01% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Gubra AS's Debt-to-Equity or its related term are showing as below:
HAM:PI3'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.09 Med: 0.35 Max: 0.91
Current: 0.09
During the past 7 years, the highest Debt-to-Equity Ratio of Gubra AS was 0.91. The lowest was 0.09. And the median was 0.35.
HAM:PI3's Debt-to-Equity is ranked better than 62.01% of 966
companies
in the Biotechnology industry
Industry Median: 0.16
vs HAM:PI3: 0.09
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Gubra AS Debt-to-Equity Related Terms
Gubra AS Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Gubra AS's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HAM:PI3 vs VRTX, REGN, ALNY: Debt-to-Equity Comparison
For the Biotechnology subindustry, Gubra AS's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gubra AS Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Gubra AS's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Gubra AS's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gubra AS (HAM:PI3) has a Debt-to-Equity of 0.09 as of Dec. 2025. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Gubra AS and its competitors. This is 74% below median its historical median of 0.35. Over the past decade, Gubra AS's Debt-to-Equity has ranged from 0.09 to 0.91. According to the industry distribution chart, Gubra AS ranks #367 out of 966 companies in the Biotechnology industry, placing it in the top 38%.
Is Gubra AS's Debt-to-Equity too high?
Gubra AS's current Debt-to-Equity of 0.09 is 74% below median its 10-year median of 0.35. Over the past 10 years, this metric has ranged from a low of 0.09 to a high of 0.91. The Biotechnology industry median Debt-to-Equity is 0.16. Gubra AS's value of 0.09 is 43.8% below this industry median. Based on the distribution chart, Gubra AS ranks #367 out of 966 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Gubra AS has a GF Score™ of 53/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Gubra AS's Debt-to-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Gubra AS ranks #367 out of 966 companies for Debt-to-Equity. This puts Gubra AS in the upper half of its industry. The industry median Debt-to-Equity is 0.16. Gubra AS's value of 0.09 is 43.8% below this benchmark. Historically, Gubra AS's own Debt-to-Equity has ranged from 0.09 to 0.91 over the past decade. While the company's 10-year median is 0.35 vs. the industry median of 0.16, Gubra AS has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 966 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Gubra AS's current Debt-to-Equity of 0.09 is 43.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Gubra AS and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gubra AS's current Debt-to-Equity is 0.09, which is 74% below median its own 10-year median of 0.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gubra AS stock overvalued right now?
Based on GuruFocus' analysis, Gubra AS (HAM:PI3) is currently considered Possible Value Trap. The stock's GF Value™ is €388.86, compared to a current price of €45.70 — trading 88.2% below its estimated fair value. The current Debt-to-Equity is 0.09, which is 74% below median its 10-year median of 0.35 and 43.8% below the Biotechnology industry median of 0.16. Gubra AS's overall GF Score™ is 53/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Gubra AS (HAM:PI3), the current Debt-to-Equity is 0.09 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gubra AS (HAM:PI3) Overvalued in 2026?
Based on GuruFocus' analysis, Gubra AS stock appears to be undervalued.
The current stock price of €45.70 is trading 88.2% below its estimated GF Value™ of €388.86.
GuruFocus considers Gubra AS to be Possible Value Trap.
Key valuation signals for HAM:PI3:
Debt-to-Equity: 0.09 (74% below median its 10-year median of 0.35)
GF Value™: €388.86 vs. price of €45.70 (88.2% below fair value)
Industry Position: 43.8% below the Biotechnology median (#367 of 966)
No single metric tells the full story. See the HAM:PI3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gubra AS is a specialized preclinical CRO and biotech company focused on peptide-based drug discovery within metabolic and fibrotic diseases. The company has two segments: Pre-clinical contract research (CRO), which derives maximum revenue and Biotech Segment. It derives maximum revenue from Pre-clinical contract research (CRO) segment. Geographically, the company operates in Europe, North America and Other regions.
53GF Score
Get the complete analysis for HAM:PI3
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:PI3 has been successfully added to your 
